Posted by Michael Wonder on 10 Dec 2015
AbbVie's Humira (adalimumab) receives Health Canada approval for the extension of the polyarticular juvenile idiopathic arthritis indication for patients between 2 and 4 years
9 December 2015 - Humira was approved in Canada in 2012 for polyarticular juvenile idiopathic arthritis in patients aged 4 to 17 years.
For more details, go to: http://www.newswire.ca/news-releases/abbvies-humira-adalimumab-receives-health-canada-approval-for-the-extension-of-the-polyarticular-juvenile-idiopathic-arthritis-indication-for-patients-between-2-and-4-years-561219751.html
